ATE554792T1 - Stabiles wachstumshormon-flüssigformulierung - Google Patents

Stabiles wachstumshormon-flüssigformulierung

Info

Publication number
ATE554792T1
ATE554792T1 AT04801396T AT04801396T ATE554792T1 AT E554792 T1 ATE554792 T1 AT E554792T1 AT 04801396 T AT04801396 T AT 04801396T AT 04801396 T AT04801396 T AT 04801396T AT E554792 T1 ATE554792 T1 AT E554792T1
Authority
AT
Austria
Prior art keywords
growth hormone
present
formulations
liquid formulation
stable growth
Prior art date
Application number
AT04801396T
Other languages
English (en)
Inventor
Advait Badkar
Sandeep Nema
Manpreet Wadhwa
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE554792T1 publication Critical patent/ATE554792T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04801396T 2003-12-23 2004-12-13 Stabiles wachstumshormon-flüssigformulierung ATE554792T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53184303P 2003-12-23 2003-12-23
PCT/IB2004/004159 WO2005063298A1 (en) 2003-12-23 2004-12-13 Stable growth hormone liquid formulation

Publications (1)

Publication Number Publication Date
ATE554792T1 true ATE554792T1 (de) 2012-05-15

Family

ID=34738712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04801396T ATE554792T1 (de) 2003-12-23 2004-12-13 Stabiles wachstumshormon-flüssigformulierung

Country Status (8)

Country Link
US (1) US8338374B2 (de)
EP (1) EP1706150B1 (de)
JP (1) JP4845741B2 (de)
AT (1) ATE554792T1 (de)
BR (1) BRPI0418115A (de)
CA (1) CA2551510C (de)
ES (1) ES2383691T3 (de)
WO (1) WO2005063298A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2008004717A1 (en) 2006-07-06 2008-01-10 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2010049488A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CN102939106B (zh) * 2010-02-24 2016-06-29 艾瑞克有限公司 蛋白质制剂
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
WO2013014196A1 (en) * 2011-07-25 2013-01-31 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
JP5487276B2 (ja) * 2012-11-12 2014-05-07 デウン カンパニー,リミテッド ヒト成長ホルモンを含有する安定した液状製剤
CA2903706C (en) * 2013-03-13 2024-01-23 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
WO2015046974A1 (ko) * 2013-09-27 2015-04-02 한미약품 주식회사 지속형 인간 성장 호르몬 제제
WO2016011281A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries Ltd. FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー/エス 高濃度インスリン製剤
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ES2153385T5 (es) * 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
SE9503679D0 (sv) * 1995-10-20 1995-10-20 Pharmacia Ab Antioxidants
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20030162711A1 (en) 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
CA2304808C (en) 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
MXPA02000404A (es) 1999-07-12 2004-05-21 Grandis Biotech Gmbh Formulaciones de hormona de crecimiento.
CN100389821C (zh) * 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
EP1329224A4 (de) * 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd Über lange zeit stabilisierte lösungen

Also Published As

Publication number Publication date
US20080125356A1 (en) 2008-05-29
ES2383691T3 (es) 2012-06-25
WO2005063298A1 (en) 2005-07-14
CA2551510A1 (en) 2005-07-14
US8338374B2 (en) 2012-12-25
JP4845741B2 (ja) 2011-12-28
EP1706150B1 (de) 2012-04-25
EP1706150A1 (de) 2006-10-04
JP2007516274A (ja) 2007-06-21
CA2551510C (en) 2013-07-30
BRPI0418115A (pt) 2007-04-17

Similar Documents

Publication Publication Date Title
ATE554792T1 (de) Stabiles wachstumshormon-flüssigformulierung
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
CO4940385A1 (es) Composiciones limpiadoras liquidas suaves antimicrobianas que se quitan enjuagando surfactantes acidos
DK1133316T3 (da) Adenovirus-formulering til genterapi
AR033059A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
DE60019902D1 (de) Echinocandin pharmazeutische zusammensetzungen
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
WO2006066888A3 (de) Alkoholischer pumpschaum
AR049084A1 (es) Composiciones de cuidado personal y concentrados para su elaboracion
AR040527A1 (es) Formulaciones de hgh en alta concentracion que contienen glicina
KR950703358A (ko) 인터루킨-1 억제제를 함유하는 제약 조성물(pharmaceutical formulations of intereukin-1 inhibitors)
ES2139021T3 (es) Composiciones germicidas de detergente-yodo que tienen un contenido reducido de detergente.
PE20070437A1 (es) FORMULACION ACUOSA hFSH
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
AR025243A1 (es) Composicion liquida de pesticida.
TR199801558T2 (xx) Stabile edilmi� b�y�me hormonu form�lasyonu ve haz�rlama y�ntemi.
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
ATE421312T1 (de) Nachschäumendes reinigungsmittel
TR200200034T2 (tr) Büyüme hormonu formülasyonları.
ECSP045349A (es) Formuilaciones liquidas de baja dosis de entecavir y uso
BRPI0511923A (pt) composições estabilizadas que compreendem um agente terapeuticamente ativo ácido cìtrico ou uma base conjugada e dioxido de cloro
AR017925A1 (es) Una formulacion acuosa para verter, topicamente aceptable, adaptada para su aplicacion externa localizada en un animal, su uso y un metodo para formularla
ATE430571T1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol- verbindungen
BR112022014240A2 (pt) Formulação farmacêutica líquida estável, e, kit
PT1171100E (pt) Composicao farmaceutica solubilizada para administracao parenteral